---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-071078"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:38:42.233066+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Replimune raises $100M in PIPE to fund RP1 commercialization; BLA filing on track for 2H 2024

## Summary
- Issued 5.67M shares at $8.82/share and 5.67M pre-funded warrants at $8.819/warrant.
- Gross proceeds ~$100M; expected closing June 14, 2024.
- Proceeds to fully scale up for RP1 commercial launch in skin cancers, potential path to profitability.
- Led by life-sciences institutional investor; Redmile, RTW, Boxer Capital participated.
- RP1 IGNYTE trial in anti-PD1 failed melanoma showed strong data; BLA submission expected 2H 2024.

## SEC filing metadata
- accession: 0001104659-24-071078
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465924071078/0001104659-24-071078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465924071078/tm2417173d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-071078
- JSON: https://secwatch.observer/filing/0001104659-24-071078.json
- Plain text: https://secwatch.observer/filing/0001104659-24-071078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.